Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience.
作者信息
Abbasi Abdul Muqtadir, Shaikh Usman, Ali Natasha, Haider Mohammad Nadir
机构信息
Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan.
Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan.
出版信息
Leuk Res Rep. 2021 Jan 28;15:100235. doi: 10.1016/j.lrr.2021.100235. eCollection 2021.
Abstract
摘要
相似文献
1
Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience.
Leuk Res Rep. 2021 Jan 28;15:100235. doi: 10.1016/j.lrr.2021.100235. eCollection 2021.
2
The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients.
Indian J Hematol Blood Transfus. 2014 Dec;30(4):231-5. doi: 10.1007/s12288-013-0244-5. Epub 2013 Feb 23.
3
4
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Ann Hematol. 2016 Oct;95(11):1777-86. doi: 10.1007/s00277-016-2774-z. Epub 2016 Aug 19.
5
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Ann Hematol. 2005 Nov;84(12):792-5. doi: 10.1007/s00277-005-1090-9. Epub 2005 Nov 12.
6
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Int J Hematol. 2019 Apr;109(4):418-425. doi: 10.1007/s12185-019-02606-0. Epub 2019 Feb 6.
7
Older and new purine nucleoside analogs for patients with acute leukemias.
Cancer Treat Rev. 2013 Dec;39(8):851-61. doi: 10.1016/j.ctrv.2013.03.006. Epub 2013 Apr 6.
8
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Cancer. 1999 Dec 1;86(11):2246-51. doi: 10.1002/(sici)1097-0142(19991201)86:11<2246::aid-cncr11>3.0.co;2-i.
9
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Ann Hematol. 2009 Feb;88(2):151-8. doi: 10.1007/s00277-008-0571-z. Epub 2008 Aug 16.
10
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Cancer. 2002 Feb 1;94(3):585-93. doi: 10.1002/cncr.10240.
本文引用的文献
1
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
Cancer Chemother Pharmacol. 2019 Jun;83(6):1191-1193. doi: 10.1007/s00280-019-03792-8. Epub 2019 Feb 13.
2
Objective assessment of WHO/ECOG performance status.
Support Care Cancer. 2019 Oct;27(10):3793-3798. doi: 10.1007/s00520-018-4597-z. Epub 2019 Feb 5.
3
Acute myeloid leukemia: 2019 update on risk-stratification and management.
Am J Hematol. 2018 Oct;93(10):1267-1291. doi: 10.1002/ajh.25214.
4
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Leuk Lymphoma. 2019 Apr;60(4):1014-1022. doi: 10.1080/10428194.2018.1508670. Epub 2018 Oct 2.
5
Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Leuk Res. 2018 May;68:51-56. doi: 10.1016/j.leukres.2018.03.006. Epub 2018 Mar 8.
6
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):767-773. doi: 10.1016/j.clml.2017.06.002. Epub 2017 Jun 19.
7
Acute lymphoblastic leukemia: a comprehensive review and 2017 update.
Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53.
8
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
9
Structural Barriers to Diagnosis and Treatment of Cancer in Low- and Middle-Income Countries: The Urgent Need for Scaling Up.
J Clin Oncol. 2016 Jan 1;34(1):14-9. doi: 10.1200/JCO.2015.61.9189. Epub 2015 Nov 17.
10
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
Zotero 插件